Cochrane · systematic review · CD009580
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D, Liu, B, Tao, W, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 70%Moderate 3 · 30%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fibrates compared with control for secondary prevention of cardiovascular disease and stroke
Population: People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Composite outcome of non‐fatal stroke, non‐fatal myocardial infarction, and vascular death Fibrates vs control | RR 0.88 [0.83, 0.94] | 12 studies · 16064 participants | Moderate |
Death from any cause during the treatment and scheduled Fibrates vs control | RR 0.98 [0.91, 1.06] | 10 studies · 13653 participants | Low |
Death from vascular causes during the treatment and scheduled Fibrates vs control | RR 0.95 [0.86, 1.05] | 10 studies · 13653 participants | Low |
Myocardial infarction (non‐fatal or fatal) during the treatment and scheduled Fibrates vs control | RR 0.86 [0.8, 0.93] | 10 studies · 13942 participants | Moderate |
Stroke (ischaemic or haemorrhagic, non‐fatal or fatal) during the treatment and scheduled Fibrates vs control | RR 1.03 [0.91, 1.16] | 6 studies · 11719 participants | Low |
Fibrates compared with control for secondary prevention of cardiovascular disease and stroke ‐ without clofibrate data
Population: People with previous clinical manifestations of cardiovascular disease, transient ischaemic attack, or stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Composite outcome of non‐fatal stroke, non‐fatal myocardial infarction, and vascular death without clofibrate Fibrates vs control | RR 0.9 [0.79, 1.03] | 7 studies · 10320 participants | Low Downgraded: imprecision |
Death from any cause during the treatment and scheduled Fibrates vs control | RR 1.01 [0.91, 1.12] | 5 studies · 7909 participants | Low Downgraded: imprecision |
Death from vascular causes during the treatment and scheduled Fibrates vs control | RR 0.98 [0.84, 1.15] | 5 studies · 7909 participants | Low Downgraded: imprecision |
Myocardial infarction (non‐fatal or fatal) during the treatment and scheduled Fibrates vs control | RR 0.85 [0.76, 0.94] | 6 studies · 8304 participants | Moderate |
Stroke (ischaemic or haemorrhagic, non‐fatal or fatal) during the treatment and scheduled Fibrates vs control | RR 0.94 [0.78, 1.14] | 3 studies · 7189 participants | Low Downgraded: imprecision |